Last week I had the pleasure of spending a few days in Boston attending two separate life science events, Device Talks and McDermott Will & Emery’s Life Sciences Dealmaking Symposium. Although I love spending time in Boston, which is booming, I wish these events had been another week as I was not at home for … Continue reading Device Talks Boston – A Recap
One of the most common questions I get asked comes from Pre-Clinical Life Science companies is why do I need insurance? I agree that pre-clinical life science companies have about as little risk as a company can have. Why they need insurance really comes down to contracts, investors and statutory regulations. If the company enters … Continue reading Common Question Friday – Why Do Pre-Clinical Companies Need Insurance?
Last week the issue of public companies having to do quarterly reports popped up in the news in a big way with the President tweeting and then speaking on the possibility of ending quarterly reporting. There are a lot of opinions out there on whether this is a good idea or bad idea. Some people … Continue reading How Changing the Reporting Period for Public Companies to Semiannual Could Impact the D&O Market